NASDAQ:CRVS - Corvus Pharmaceuticals, Inc.
$5.41
 $-0.64
-10.58%
4:00PM EDT
2019-07-22
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CRVS     avg for
industry  
  avg for
sector  
42 stocks weight:  30. 93   0. 00   0. 00  
42 stocks rank:  2. 91 K 1. 35 K 799. 74  
# analyst opinions:  4. 00   12. 76   13. 14  
mean recommendation:  1. 50   2. 11   2. 07  

quick ratio:  12. 30   5. 61   1. 85  
current ratio:  12. 39   6. 00   2. 31  

target price low:  6. 00   75. 88   108. 31  
target price avg:  10. 75   97. 27   130. 10  
target price high:  14. 00   124. 58   149. 02  
1-yr high:  11. 08   104. 89   135. 09  
last close:  5. 41   79. 79   118. 76  
50-day avg:  4. 33   79. 39   116. 18  
200-day avg:  5. 01   81. 61   114. 52  
1-yr low:  3. 29   62. 76   94. 70  
volume:  257. 84 K 2. 99 M 4. 43 M
50-day avg volume:  177. 52 K 3. 39 M 4. 22 M
200-day avg volume:  113. 99 K 3. 13 M 4. 83 M

1-day return:  -10. 58 % 0. 33 % 0. 14 %
this week return:  -10. 58 % 0. 33 % 0. 14 %
12-wk return:  33. 25 % 1. 00 % 3. 51 %
52-wk return:  -46. 98 % 0. 58 % 10. 25 %

enterprise value (EV):  75. 39 M 44. 78 B 115. 63 B
market cap:  158. 66 M 38. 01 B 103. 29 B
EBITDA:  -46. 07 M 4. 47 B 7. 73 B
enterprise multiple (EV/EBITDA):  -1. 64   2. 11   11. 26  
total debt:  3. 77 M 11. 72 B 16. 76 B
debt/equity:  3. 74   61. 22   124. 43  
net income (common):  -44. 28 M 2. 06 B 3. 79 B

shares outstanding:  29. 33 M 562. 08 M 1. 27 B
shares:  11. 01 M 573. 33 M 1. 26 B
shares short:  1. 65 M 11. 60 M 12. 29 M
shares short prior month:  1. 18 M 9. 81 M 12. 46 M
short ratio:  11. 20   5. 88   3. 41  
short % of float:  11. 95 % 6. 88 % 2. 72 %
total cash/share:  3. 61   10. 62   8. 83  
total cash:  105. 81 M 6. 17 B 5. 72 B
free cash flow:  -24. 29 M 3. 08 B 3. 10 B
operating cash flow:  -38. 93 M 3. 99 B 4. 08 B

book value:  3. 43   12. 74   26. 25  
price/book:  1. 58   4. 38   9. 01  
operating margins:  0. 00 % -319. 65 % -29. 05 %
EBITDA margins:  0. 00 % 11. 82 % 24. 13 %
profit margins:  0. 00 % 5. 62 % 14. 29 %
gross margins:  0. 00 % 34. 75 % 57. 07 %

1-yr max volatility:  25. 67 % --- ---
1-yr mean volatility:  3. 34 % 1. 95 % 1. 25 %

1-yr EPS:  -1. 52   1. 58   3. 82  
forward EPS:  -1. 69   3. 16   6. 65  
P/E:  -3. 57   0. 21   31. 97  
forward P/E:  -3. 58   4. 95   15. 14  
PE/G:  0. 37   0. 74   0. 13  
growth:  -9. 53 % 295. 81 % 85. 47 %
earnings high:  -0. 42   0. 84   1. 56  
earnings avg:  -0. 43   0. 65   1. 45  
earnings low:  -0. 47   0. 40   1. 35  
revenue high:  -0. 00   2. 70 B 8. 76 B
revenue avg:  -0. 00   2. 64 B 8. 62 B
revenue low:  -0. 00   2. 58 B 8. 45 B
return on assets:  -22. 45 % -3. 43 % 4. 51 %
return on equity:  -37. 22 % -104. 30 % 140. 44 %

beta (1yr vs S&P500):  1. 37   1. 27   0. 91  
sharpe (1yr):  -0. 52   0. 20   0. 80  

held % insiders:  5. 09 % 6. 63 % 3. 46 %
held % institutions:  86. 18 % 76. 45 % 67. 87 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-22 : CRVS
.    103.822 =       103.822 :: --> INITIAL WEIGHT <--
.    - 1.517 =       102.305 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.984 =       305.233 :: P/E factor
.    x 1.278 =       390.221 :: PE/G factor
.      x 1.4 =       546.467 :: beta factor
.    x 0.826 =       451.298 :: sharpe factor
.    x 2.065 =       931.734 :: current ratio factor
.    x 1.043 =        972.09 :: quick ratio factor
.    x 1.044 =      1014.559 :: short ratio factor
.    x 1.008 =       1022.52 :: price-to-book factor
.     x 1.03 =      1053.314 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.759 =       2906.34 :: sector+industry 1-year gains factor
.     x 1.01 =       2935.36 :: industry 12-weeks return factor
.    x 1.309 =      3843.462 :: industry 2-weeks return factor
.     x 1.23 =      4726.052 :: 5-day avg > 200-day avg
.    x 2.211 =     10450.065 :: 5-day avg > 50-day avg
.     x 0.94 =      9821.759 :: "drift" penalty 1 days ago
.    x 0.994 =      9765.399 :: "drift" penalty 4 days ago
.    x 0.939 =      9167.734 :: "drift" penalty 5 days ago
.    / 2.181 =      4203.896 :: overall "drift" factor
.    x 0.515 =      2163.036 :: largest single-day jump factor
.    x 0.085 =       183.775 :: low price factor
.    x 2.309 =       424.263 :: notable returns + performance factor
.    x 3.765 =      1597.374 :: performance vs s&p500 factor
.                               --> PROJECTIONS <--
.    x 0.846 =      1351.662 :: forward EPS factor
.    x 0.944 =      1276.109 :: forward P/E factor
.    x 1.184 =      1510.862 :: industry recommendation factor
.    x 2.642 =      3991.083 :: company recommendation factor
.    x 1.002 =      3997.147 :: factor historical industry gain for week 29
.     x 1.41 =      5634.908 :: target low factor
.    x 1.331 =      7501.019 :: target mean factor
.    x 1.053 =      7897.998 :: target high factor
.    x 5.001 =     39500.704 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        14.098 :: reduced for readability
.   + 16.828 =        30.926 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     30.926 :: FINAL WEIGHT for NASDAQ:CRVS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org